Zymeworks, an early-stage biotech developing antibodies that target HER2 tumors, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The company plans to dual list on the NYSE and Toronto Stock Exchange under the symbol ZYME.
The Vancouver, Canada-based company was founded in 2003 and booked $11 million in revenue for the 12 months ended December 31, 2016. Zymeworks filed confidentially on December 13, 2016. Citi, Barclays and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
